REPLACING: Antisoma's Preliminary Results for the Year Ended 30 June 2004
16 sept. 2004 05h51 HE
|
Antisoma plc
LONDON, Sept. 16, 2004 (PRIMEZONE) -- Cancer drug development company Antisoma plc (LSE:ASM) today announces its preliminary results for the year ended 30 June 2004.
Announced today
* AS1404...
Antisoma's Preliminary Results for the Year Ended 30 June 2004
16 sept. 2004 02h18 HE
|
Antisoma plc
LONDON, Sept. 16, 2004 (PRIMEZONE) -- Cancer drug development company Antisoma plc (LSE:ASM) today announces its preliminary results for the year ended 30 June 2004.
Announced today
* AS1404...
Antisoma plc reports Q3 results
13 mai 2004 02h01 HE
|
Antisoma plc
LONDON, May 13, 2004 (PRIMEZONE) -- Antisoma plc (LSE:ASM), the biotechnology company developing novel anti-cancer drugs, today announces its results for the three months ended 31 March 2004.
...
Antisoma plc Announces Findings Presented at AACR
29 mars 2004 01h02 HE
|
Antisoma plc
LONDON, UK, March 29, 2004 (PRIMEZONE) -- Antisoma plc, the biopharmaceutical company specialising in the development of novel anti-cancer drugs, announces the presentation of promising new data from...
Antisoma plc -- R&D Update: AS1404 Advancing to Phase II Trials; AS1405 Starts Clinical Trials in Brain Cancer
22 mars 2004 02h02 HE
|
Antisoma plc
LONDON, March 22, 2004 (PRIMEZONE) -- Antisoma plc (LSE:ASM), the biopharmaceutical company specialising in the development of novel anti-cancer drugs, will today hold an R&D update for analysts...
Ursula Ney Joins Antisoma as Chief Operating Officer
25 févr. 2004 02h05 HE
|
Antisoma plc
LONDON, Feb. 24, 2004 (PRIMEZONE) -- Antisoma plc, the biopharmaceutical company specialising in the development of novel anti-cancer drugs, today announces the appointment of Dr Ursula Ney as Chief...
Antisoma in-licenses telomerase inhibitor programme from Cancer Research Technology
10 sept. 2003 02h04 HE
|
Antisoma plc
LONDON, Sept. 10, 2003 (PRIMEZONE) -- Antisoma plc, (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF) the biopharmaceutical company specialising in novel anti-cancer drugs, today announces that it has...
Antisoma Acquires Cytogen's Royalty Rights To R1549
09 sept. 2003 02h08 HE
|
Antisoma plc
LONDON, and PRINCETON, N.J., Sept. 9, 2003 (PRIMEZONE) -- Antisoma plc (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF), a United Kingdom-based biopharmaceutical company, and Cytogen Corporation...
Antisoma plc -- Antisoma to de-list from Nasdaq Europe because of forthcoming closure of market
26 août 2003 02h05 HE
|
Antisoma plc
London, UK, August 26, 2003 (PRIMEZONE) -- Antisoma (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF), the UK-based biopharmaceutical company, today announces that it has received approval for a...
Antisoma plc: Results Presented from AS1403 Phase I Biodistribution Study
22 août 2003 02h02 HE
|
Antisoma plc
LONDON, Aug. 22, 2003 (PRIMEZONE) -- Antisoma (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF) announces that results from its phase I biodistribution study of AS1403 (formerly TheraFab) will be...